A Randomised, Double-blind, Parallel Group, Multi-centre, Phase II Study to Assess the Efficacy and Safety of Best Support Care (BSC) Plus ZD6474(Vandetanib) 300 mg, BSC Plus ZD6474(Vandetanib) 100 mg, and BSC Plus Placebo in Patients With Inoperable Hepatocellular Carcinoma (HCC)
Phase of Trial: Phase II
Latest Information Update: 13 Oct 2016
At a glance
- Drugs Vandetanib (Primary)
- Indications Liver cancer
- Focus Biomarker; Therapeutic Use
- Sponsors Sanofi
- 12 Jan 2012 Results published in the Journal of Hepatology.
- 12 Oct 2009 Primary endpoint 'Objective clinical response rate' has not been met in the primary treatment phase.
- 12 Oct 2009 Results from the primary treatment phase have been presented at the 15th European Cancer Conference and the 34th Congress of the European Society for Medical Oncology.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History